Target intelligence / Profile preview

Y+L amino acid transporter 1 (SLC7A7)

Target
SLC7A7
Molecular classification
Transporter, Solute carrier family (SLC), Heterodimeric cationic amino acid transporter (light subunit)
01

Overview

Y+L amino acid transporter 1 (encoded by SLC7A7) is the light subunit of a sodium-independent, heterodimeric cationic amino acid transporter, which associates with the heavy chain SLC3A2 to form system y+L. This system facilitates the bidirectional exchange of cationic amino acids (notably lysine, arginine, ornithine) and large neutral amino acids across epithelial cell membranes in the intestine and kidney, playing an essential role in amino acid homeostasis. Mutations in SLC7A7 disrupt this transport, causing lysinuric protein intolerance (LPI), an autosomal recessive disorder with symptoms derived from defective absorption and reabsorption of basic amino acids. Beyond its role in amino acid transport, SLC7A7 also modulates immune responses in monocytes/macrophages and is implicated in disease states such as tumor progression and disorders of pregnancy[1][2][4][5][6].

Other names
Y+L amino acid transporter 1SLC7A7Y+LAT1y+LAT-1LAT3LPIMOP-2Monocyte amino acid permease 2y(+)L-type amino acid transporter 1solute carrier family 7 member 7solute carrier family 7 (amino acid transporter light chain, y+L system), member 7solute carrier family 7 (cationic amino acid transporter, y+ system), member 7
02

Mechanism of action

Substrate competition for transport (as in high-dose amino acid supplementation); Restoration or bypassing of defective transport function (in LPI via therapeutic diet)

03

Biological functions

Amino acid transmembrane transportRegulation of amino acid homeostasisImmune regulation (modulation of macrophage activation and inflammatory responses)Nitric oxide synthesis (via L-arginine transport)
04

Disease associations

Lysinuric protein intolerance (LPI)Cancer (notably glioblastoma)Autoinflammatory and immune-mediated conditionsPossible role in gestational disorders (e.g., pre-eclampsia, intrauterine growth restriction)
05

Safety considerations

Autosomal recessive loss-of-function mutations cause multisystem disease, especially LPI, which can result in life-threatening hyperammonemia, neurologic, pulmonary, and immune complications if not properly managedSelectivity and redundancy within the amino acid transporter families present significant challenges if developing inhibitors or modulators
06

Biomarkers

Elevated urinary excretion of cationic amino acids (lysine, arginine, ornithine)Reduced plasma levels of cationic amino acidsGenetic variants in SLC7A7 (diagnostic marker for LPI)

Beyond the preview

Go deeper on Y+L amino acid transporter 1 (SLC7A7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Y+L amino acid transporter 1 (SLC7A7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call